Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more
Market Cap & Net Worth: Amarin Corporation PLC (AMRN)
Amarin Corporation PLC (NASDAQ:AMRN) has a market capitalization of $320.80 Million ($320.80 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12798 globally and #5418 in its home market, demonstrating a 9.67% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amarin Corporation PLC's stock price $15.42 by its total outstanding shares 20803957 (20.80 Million).
Amarin Corporation PLC Market Cap History: 2015 to 2026
Amarin Corporation PLC's market capitalization history from 2015 to 2026. Data shows growth from $39.32 Million to $320.80 Million (21.79% CAGR).
Index Memberships
Amarin Corporation PLC is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.01% | #347 of 976 |
|
NASDAQ Composite
IXIC
|
$33.26 Trillion | 0.00% | #1253 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.02% | #194 of 263 |
Weight: Amarin Corporation PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Amarin Corporation PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amarin Corporation PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.59x
Amarin Corporation PLC's market cap is 1.59 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $64.08 Million | $130.08 Million | -$86.35 Million | 0.49x | N/A |
| 2017 | $83.42 Million | $181.10 Million | -$67.86 Million | 0.46x | N/A |
| 2018 | $283.14 Million | $229.21 Million | -$116.44 Million | 1.24x | N/A |
| 2019 | $446.04 Million | $429.75 Million | -$22.64 Million | 1.04x | N/A |
| 2020 | $101.73 Million | $614.06 Million | -$18.00 Million | 0.17x | N/A |
| 2021 | $70.11 Million | $583.19 Million | $7.73 Million | 0.12x | 9.07x |
| 2022 | $25.17 Million | $369.19 Million | -$105.80 Million | 0.07x | N/A |
| 2023 | $18.10 Million | $306.91 Million | -$59.11 Million | 0.06x | N/A |
| 2024 | $10.09 Million | $228.61 Million | -$82.18 Million | 0.04x | N/A |
| 2025 | $290.32 Million | $182.75 Million | -$38.80 Million | 1.59x | N/A |
Competitor Companies of AMRN by Market Capitalization
Companies near Amarin Corporation PLC in the global market cap rankings as of March 18, 2026.
Key companies related to Amarin Corporation PLC by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Amarin Corporation PLC Historical Marketcap From 2015 to 2026
Between 2015 and today, Amarin Corporation PLC's market cap moved from $39.32 Million to $ 320.80 Million, with a yearly change of 21.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $320.80 Million | +10.50% |
| 2025 | $290.32 Million | +2777.32% |
| 2024 | $10.09 Million | -44.25% |
| 2023 | $18.10 Million | -28.10% |
| 2022 | $25.17 Million | -64.09% |
| 2021 | $70.11 Million | -31.08% |
| 2020 | $101.73 Million | -77.19% |
| 2019 | $446.04 Million | +57.53% |
| 2018 | $283.14 Million | +239.40% |
| 2017 | $83.42 Million | +30.19% |
| 2016 | $64.08 Million | +62.96% |
| 2015 | $39.32 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Amarin Corporation PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $320.80 Million USD |
| MoneyControl | $320.80 Million USD |
| MarketWatch | $320.80 Million USD |
| marketcap.company | $320.80 Million USD |
| Reuters | $320.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.